There is no evidence from these trials that the detection and removal of adenomas has decreased the prevalence of colorectal cancer in the screened populations. Thus, to date there is direct evidence that screening with Hemoccult has a clinically small but statistically significant cancer specific mortality benefit for annual screening but not biennial screening.
Un essai a montr´ e e une baisse nette, statistiquement significative, de la mortalit´ sp´ cifique e e au cancer<5> associ´ e a l’´ preuve H´ moccult, lorsque celle-ci est e ` e e effectu´ e chaque ann´ e, mais non aux deux ans; deux essais ont e e montr´ une diminution de la mortalit´ sp´ cifique au cancer dans le e e e groupe ayant fait l’objet du d´ pistage, mais les diff´ rences n’atteignaient e e pas la signification statistique<6,9>.